Skip to content

US · ABCL · BIOTECHNOLOGY

AbCellera Biologics Inc. (ABCL) intrinsic value and stock valuation

$9.69as of 2026-11-21 · Mkt cap 1.81B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

AbCellera Biologics Inc. DCF and intrinsic value

InvestorsCraft values ABCL with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ABCL’s statements →

AbCellera Biologics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Vancouver, BC V5Y 1G6 abcellera.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$75.1M-20.3% 5y CAGRd
20182025
Net income
-$-146.41M
20182025
Free cash flow
-$-174.07M
20182025
Total equity
$966.9M+3.1% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$75.1M$28.8M$38M$485.4M$375.2M
Operating income-$-217.1M-$-314.77M-$-237.21M$216.5M$204.4M
Net income-$-146.41M-$-162.86M-$-146.4M$158.5M$153.5M
EPSd-$-490.14K-$-553.32K-$-506.28K$503.5K$482.1K
Operating cash flow-$-131.29M-$-108.56M-$-43.88M$277.4M$244.6M
Capital expenditure-$-42.77M-$-78.4M-$-77.51M-$-72.66M-$-58.45M
Free cash flow-$-174.07M-$-186.95M-$-121.38M$204.7M$186.1M
Total assets$1.36B$1.36B$1.49B$1.54B$1.32B
Total debt$143.2M$65.4M$77.4M$82.3M$40.1M
Net debt$14.7M-$-90.96M-$-55.94M-$-304.28M-$-436.08M
Total equity$966.9M$1.06B$1.15B$1.23B$1.03B
Cash and short-term investments$533.8M$625.6M$760.6M$886.5M$723M
Income statement
20252024202320222021
Revenue$75.1M$28.8M$38M$485.4M$375.2M
Cost of revenue$28.8M$0.00$0.00$66.4M$45.5M
Gross profit$46.3M$28.8M$38M$419M$329.7M
Research and development expenses$186.8M$167.3M$175.7M$107.9M$62.1M
Selling, general and administrative expenses$76.6M$85.5M$75.2M$66.8M$48.8M
Other expenses$0.00$90.9M$24.4M$27.8M$14.5M
Operating expenses$263.4M$343.6M$275.2M$202.5M$125.3M
Cost and expenses$292.2M$343.6M$275.2M$268.9M$170.8M
Interest income$28.3M$38.5M$42.3M$16.1M$3.33M
Interest expense$0.00$0.00$0.00$4.04M$5.22M
Depreciation and amortization$28.8M$97M$30.9M$33.1M$17.3M
Ebitda-$-148.77M-$-204.15M-$-192.16M$260.2M$239.2M
Operating income-$-217.1M-$-314.77M-$-237.21M$216.5M$204.4M
Total other income/expenses, net$39.5M$114.4M$63.2M$22.6M$14.7M
Income before tax-$-177.59M-$-200.4M-$-174.03M$239.1M$219.2M
Income tax expense-$-31.18M-$-37.54M-$-27.63M$80.6M$65.7M
Net income-$-146.41M-$-162.86M-$-146.4M$158.5M$153.5M
Weighted average shares outstanding$298.7M$294.3M$289.2M$285.1M$275.8M
Weighted average diluted shares outstanding$298.7M$294.3M$289.2M$314.8M$318.3M
Balance sheet
20252024202320222021
Cash and short-term investments$533.8M$625.6M$760.6M$886.5M$723M
Net receivables$153.4M$92.1M$64.4M$103.4M$174.9M
Inventory$6.34M$0.00$1.11M$1.53M$1.67M
Total current assets$728.2M$751.4M$872M$1.03B$929.8M
Property, plant and equipment, net$428M$340.4M$287.7M$217.3M$111.6M
Goodwill and intangible assets$86.2M$89.9M$168.2M$179.3M$196.2M
Long-term investments$62.6M$82.3M$65.9M$72.5M$50.3M
Total non-current assets$628.7M$609.2M$616.1M$515.4M$388.8M
Total assets$1.36B$1.36B$1.49B$1.54B$1.32B
Accounts payable$25.2M$34.4M$25.5M$14.8M$14.9M
Short-term debt$5.82M$4.62M$6.16M$5.58M$3.65M
Deferred revenue$22.5M$21.2M$19M$21.6M$7.54M
Total current liabilities$64.3M$76.6M$119M$118.3M$120.7M
Long-term debt$137.4M$60.7M$71.2M$76.7M$36.4M
Deferred revenue, non-current$174.5M$155.6M$104.1M$60.3M$60.8M
Total non-current liabilities$325.7M$227.9M$216.8M$189.3M$172.2M
Capital lease obligations$143.2M$65.4M$77.4M$82.3M$40.1M
Total liabilities$390.1M$304.5M$335.8M$307.6M$292.8M
Common stock$802.3M$777.2M$753.2M$734.4M$722.4M
Retained earnings-$-29.48M$116.9M$279.8M$426.2M$267.7M
Accumulated other comprehensive income (loss)-$-4.23M-$-4.38M-$-1.72M-$-1.39M$280K
Total equity$966.9M$1.06B$1.15B$1.23B$1.03B
Total investments$467.9M$551.6M$693.2M$572.5M$297.2M
Total debt$143.2M$65.4M$77.4M$82.3M$40.1M
Net debt$14.7M-$-90.96M-$-55.94M-$-304.28M-$-436.08M
Cash flow statement
20252024202320222021
Net income-$-146.41M-$-162.86M-$-146.4M$158.5M$153.5M
Depreciation and amortization$22.2M$97M$30.9M$33.1M$17.3M
Stock-based compensation$55.8M$67.6M$64.2M$49.5M$30.7M
Change in working capital-$-70.69M-$-25.84M$13.2M$29.8M$41.7M
Accounts receivable-$-55.62M-$-75.12M-$-45.93M-$-22.71M$22.5M
Inventory$0.00$0.00$18.3M$0.00$0.00
Accounts payable$3.46M$10.6M-$-15.1M$1.07M$1.4M
Net cash provided by operating activities-$-131.29M-$-108.56M-$-43.88M$277.4M$244.6M
Investments in property, plant and equipment-$-42.77M-$-78.4M-$-77.51M-$-72.66M-$-58.45M
Acquisitions, net-$-7.14M-$-19.63M-$-13.69M-$-25.68M-$-11.46M
Net cash used for investing activities$87.8M$121.4M-$-221.11M-$-352.62M-$-332.25M
Common stock issued$0.00$0.00$0.00$0.00$4.62M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$14.1M$12.8M$10.4M-$-1.63M-$-3.89M
Net change in cash-$-28.37M$23M-$-254.04M-$-86.49M-$-92.97M
Cash at end of period$155.3M$183.6M$160.6M$414.7M$501.1M
Operating cash flow-$-131.29M-$-108.56M-$-43.88M$277.4M$244.6M
Capital expenditure-$-42.77M-$-78.4M-$-77.51M-$-72.66M-$-58.45M
Free cash flow-$-174.07M-$-186.95M-$-121.38M$204.7M$186.1M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About AbCellera Biologics Inc.

        AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

        CEO
        Carl Hansen
        Employees
        562
        Beta
        1.15

        Explore

        Frequently asked questions

        What is the intrinsic value of AbCellera Biologics Inc. (ABCL)?

        AbCellera Biologics Inc. (ABCL) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ABCL undervalued?

        ABCL trades at a price of $9.69 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.